Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Covalent-103: A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study of Bmf-500, an Oral Covalent FLT3 Inhibitor, in Adults with Acute Leukemia (AL)

Marcello Rotta, Farhad Ravandi, Mitul Gandhi, Paul B. Koller, Gary J. Schiller, Courtney Follit, Mona Vimal, Stephan W. Morris, Sanchita Mourya, Thomas Butler, Eunice S. Wang

Blood (2023) 142 (Supplement 1): 1546.

https://doi.org/10.1182/blood-2023-182361

Published: 2023

Journal Articles

A Phase 1 Study of NKX101, a Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Therapy, with Fludarabine and Cytarabine in Patients with Acute Myeloid Leukemia

Craig S Sauter, Gautam Borthakur, Luke Mountjoy, Marcello Rotta, Hongtao Liu, Hemant S. Murthy, Ming Lin, James Trager, Cornell Chang, Nishi Kothari, David Shook, Carlos Bachier

Blood (2023) 142 (Supplement 1): 2097.

https://doi.org/10.1182/blood-2023-173582

Published: 2023

Journal Articles

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Blood (2021) 138 (22): 2278–2289.

https://doi.org/10.1182/blood.2021012021

Published: 2021

Includes: Supplemental data

Journal Articles

Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213)

Corey Cutler, MD MPH, FRCPC, Stephanie J. Lee, MDMPH, Sally Arai, MD MS, Marcello Rotta, MD, Behyar Zoghi, MD, Aravind Ramakrishnan, MD, David Eiznhamer, PhD, Olivier Schueller, PhD, Zhongming Yang, PhD, Laurie S. Green, MD, Sanjay K. Aggarwal, MD, Bruce R. Blazar, MD, Steven Z. Pavletic, MD MS, Madan Jagasia, MBBS, MS, MMHC

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-139445

Published: 2020

Journal Articles

A Phase 1 Study of Sea-CD70 in Myeloid Malignancies

Ahmed Aribi, MD, Anjali S Advani, MD, William Donnellan, MD, Amir T. Fathi, MD, Marcello Rotta, MD, Benjamin K. Tomlinson, MD, Pankit Vachani, MD, Jay Yang, MD, Phoenix Ho, MD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136203

Published: 2020

Journal Articles

A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS)

Carlos Bachier, MD, Gautam Borthakur, MD, Chitra Hosing, MD, William Blum, MD, Marcello Rotta, MD, Paulius Ojeras, Brian Barnett, MD, Kanya Rajangam, MD PhD, Navneet S. Majhail, MD MS, Sarah Nikiforow, MD PhD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-134625

Published: 2020

Journal Articles

Epidemiology and Real-World Treatment of Chronic Graft-Versus-Host Disease Post Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis

Carlos R. Bachier, MD, Sanjay K. Aggarwal, MD, Kalin Hennegan, MPH, Andrew Milgroom, Kevin Francis, Marcello Rotta, MD

Blood (2019) 134 (Supplement_1): 2109.

https://doi.org/10.1182/blood-2019-130563

Published: 2019

Journal Articles

Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled Study

Charles F. Lemaistre, MD, Ju-Hsien Chao, DO, Tonya Cox, BSN, RN, Jose Carlos Cruz, MD, William B. Donnellan, MD, Alireza Eghtedar, MD, Jared Holder, MA, Suman Kambhampati, MD, Shahbaz Malik, Michael B. Maris, MD, Marcello Rotta, MD, Frank Thomas Slovick, MD, Minoo Battiwalla, MD

Blood (2019) 134 (Supplement_1): 4780.

https://doi.org/10.1182/blood-2019-130640

Published: 2019

Journal Articles

The Effect Of Donor and Recipient Statin Treatment On Infections After Allogeneic Hematopoietic Cell Transplantation

Sachiko Seo, MD, Michael Boeckh, MD, Barry E. Storer, PhD, Mark M Schubert, DDS, MSD, Marcello Rotta, MD, Brenda M. Sandmaier, MD, Marco Mielcarek, MD

Blood (2013) 122 (21): 4548.

https://doi.org/10.1182/blood.V122.21.4548.4548

Published: 2013

Journal Articles

Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma

Blood (2011) 117 (24): 6721–6727.

https://doi.org/10.1182/blood-2011-03-339945

Published: 2011

Journal Articles

Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma

Blood (2010) 116 (21): 525.

https://doi.org/10.1182/blood.V116.21.525.525

Published: 2010

Journal Articles

Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation

Marcello Rotta, Barry E. Storer, Rainer F. Storb, Paul J. Martin, Shelly Heimfeld, Amanda Peffer, David G. Maloney, H. Joachim Deeg, Brenda M. Sandmaier, Frederick R. Appelbaum, Marco Mielcarek

Blood (2010) 115 (6): 1288–1295.

https://doi.org/10.1182/blood-2009-08-240358

Published: 2010

Journal Articles

Donor Statin Treatment Protects against Severe Acute Graft-Versus-Host Disease After Related Allogeneic Hematopoietic Cell Transplantation.

Marcello Rotta, Barry E Storer, Rainer F Storb, Paul J Martin, Shelly Heimfeld, Amanda Peffer, Brenda M Sandmaier, David G Maloney, H. Joachim Deeg, Frederick R Appelbaum, Marco Mielcarek

Blood (2009) 114 (22): 2227.

https://doi.org/10.1182/blood.V114.22.2227.2227

Published: 2009

Journal Articles

Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM).

Marcello Rotta, MD, Barry E Storer, Thoralf Lange, MD, Michael Pulsipher, MD, Judith Shizuru, MD, PhD, Benedetto Bruno, MD, PhD, Peter A. McSweeney, MD, Edward Agura, MD, Thomas Chauncey, MD, PhD, Frederick R Appelbaum, MD, William Bensinger, MD, Brenda M Sandmaier, MD, Rainer F Storb, George E. Georges, MD, David G Maloney, MD, PhD

Blood (2009) 114 (22): 3391.

https://doi.org/10.1182/blood.V114.22.3391.3391

Published: 2009

Journal Articles

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting

Marcello Rotta, Barry E. Storer, Firoozeh Sahebi, Judith A. Shizuru, Benedetto Bruno, Thoralf Lange, Edward D. Agura, Peter A. McSweeney, Michael A. Pulsipher, Parameswaran Hari, Richard T. Maziarz, Thomas R. Chauncey, Frederick R. Appelbaum, Mohamed L. Sorror, William Bensinger, Brenda M. Sandmaier, Rainer F. Storb, David G. Maloney

Blood (2009) 113 (14): 3383–3391.

https://doi.org/10.1182/blood-2008-07-170746

Published: 2009

Includes: Supplemental data

Journal Articles

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo

Blood (2009) 113 (14): 3375–3382.

https://doi.org/10.1182/blood-2008-07-167379

Published: 2009

Journal Articles

Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.

Marcello Rotta, MD, Barry Storer, PhD, Firoozeh Sahebi, MD, Judith A. Shizuru, MD, PhD, Benedetto Bruno, MD, PhD, Thoralf Lange, MD, Peter A. McSweeney, MD, Michael Pulsipher, MD, Parameswaran Hari, MD, MS, Richard Thomas Maziarz, MD, Edward Agura, MD, Thomas Chauncey, MD, PhD, Frederick Appelbaum, MD, William Bensinger, MD, Brenda Sandmaier, MD, PhD, Rainer Storb, MD, David G. Maloney, MD, PhD

Blood (2008) 112 (11): 1130.

https://doi.org/10.1182/blood.V112.11.1130.1130

Published: 2008

Journal Articles

Long-Term Outcome of Autologous Followed by Nonmyeloablative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM).

Marcello Rotta, MD, Barry Storer, PhD, Firoozeh Sahebi, MD, Judith A. Shizuru, MD PhD, Bruno Benedetto, MD PhD, Thoralf Lange, MD, Peter A. McSweeney, MD, Michael A. Pulsipher, MD, Parameswaran Hari, MD, Richard T. Maziarz, MD, Edward D. Agura, MD, Thomas Chauncey, MD, Frederick R. Appelbaum, MD, Mohamed L. Sorror, MD, William Bensinger, MD, Brenda M. Sandmaier, MD PhD, Rainer F. Storb, MD, David G. Maloney, MD PhD

Blood (2007) 110 (11): 3029.

https://doi.org/10.1182/blood.V110.11.3029.3029

Published: 2007

Journal Articles

Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma.

Blood (2006) 108 (11): 3158.

https://doi.org/10.1182/blood.V108.11.3158.3158

Published: 2006

Journal Articles

Exhaled Nitric Oxide (eNO) and Pulmonary Function after Total Body Irradiation (TBI) Based Non Myeloablative Conditioning Regimens and Allogeneic Hematopoietic Cell Transplant.

Luisa Giaccone, MD, Caterina B. Bucca, MD, Roberto Sorasio, MD, Marcello Rotta, MD, Gabriele Aitoro, MD, Erica Panaro, MD, Luisa Brussino, MD, Giovanni Rolla, MD, Mario Boccadoro, MD, Benedetto Bruno, MD, PhD

Blood (2005) 106 (11): 5311.

https://doi.org/10.1182/blood.V106.11.5311.5311

Published: 2005

NARROW

Covalent-103: A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study of Bmf-500, an Oral Covalent FLT3 Inhibitor, in Adults with Acute Leukemia (AL)

A Phase 1 Study of NKX101, a Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Therapy, with Fludarabine and Cytarabine in Patients with Acute Myeloid Leukemia

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213)

A Phase 1 Study of Sea-CD70 in Myeloid Malignancies

A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS)

Epidemiology and Real-World Treatment of Chronic Graft-Versus-Host Disease Post Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis

Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled Study

The Effect Of Donor and Recipient Statin Treatment On Infections After Allogeneic Hematopoietic Cell Transplantation

Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma

Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma

Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation

Donor Statin Treatment Protects against Severe Acute Graft-Versus-Host Disease After Related Allogeneic Hematopoietic Cell Transplantation.

Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM).

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo

Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.

Long-Term Outcome of Autologous Followed by Nonmyeloablative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM).

Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma.

Exhaled Nitric Oxide (eNO) and Pulmonary Function after Total Body Irradiation (TBI) Based Non Myeloablative Conditioning Regimens and Allogeneic Hematopoietic Cell Transplant.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only